Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

被引:17
|
作者
Zhu, Cheng-Liang [2 ,4 ,7 ]
Luo, Xiaomin [1 ]
Tian, Tian [3 ]
Rao, Zijian [2 ]
Wang, Hanlin [10 ]
Zhou, Zhesheng [2 ]
Mi, Tian [5 ]
Chen, Danni [2 ]
Xu, Yongjin [9 ]
Wu, Yizhe
Che, Jinxin [3 ]
Zhou, Yubo [1 ,5 ,6 ]
Li, Jia [1 ,5 ,6 ]
Dong, Xiaowu [3 ,7 ,8 ]
机构
[1] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[4] Ctr Drug Safety Evaluat & Res ZJU, Hangzhou 310058, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan Tsuihang New Di 528400, Guangdon, Peoples R China
[7] Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310016, Peoples R China
[8] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
[9] Canc Hosp Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Hangzhou 310005, Peoples R China
[10] Fudan Univ, Sch Pharm, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; Protein kinase B; PROTAC; Chemical degrader; Rational design; MANTLE CELL LYMPHOMA; BIOLOGICAL EVALUATION; PATHWAY; DEGRADATION; INHIBITION; DERIVATIVES; BTK; IBRUTINIB; MK-2206; TARGET;
D O I
10.1016/j.ejmech.2022.114459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AKT and associated signaling pathways have been recognized as promising therapeutic targets for decades, and growing evidence indicates that inhibition or degradation of cellular AKT are viable strategies to treat cancer. Guided by an in silico modeling approach for rational linker design and based on our previous work in this field, we herein efficiently synthesized a small group of cereblon-recruiting AKT PROTAC molecules and identified a highly potent AKT degrader B4. Compared to the existing AKT degraders, B4 has a structurally unique AKT targeting warhead derived from the pyrazole-furan conjugated piperidine derivatives. It induces selective degradation of all three isoforms of AKT and exhibits efficacious anti-proliferation against several human hematological cancers. Notably, B4 demonstrates potent inhibition of AKT downstream signaling superior to its parental inhibitor. Together with its active analogs, B4 expands the arsenal of AKT chemical degraders as a valuable probe to uncover AKTs new functions and as a potential drug candidate to treat cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
    Zhou, Haibin
    Bai, Longchuan
    Xu, Renqi
    Zhao, Yujun
    Chen, Jianyong
    McEachern, Donna
    Chinnaswamy, Krishnapriya
    Wen, Bo
    Dai, Lipeng
    Kumar, Praveen
    Yang, Chao-Yie
    Liu, Zhaomin
    Wang, Mi
    Liu, Liu
    Meagher, Jennifer L.
    Yi, Han
    Sun, Duxin
    Stuckey, Jeanne A.
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (24) : 11280 - 11300
  • [2] Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2
    Wen, Chaowei
    Gajjala, Prathibha R.
    Liu, Yihan
    Chen, Bingzhong
    Bal, Mehtab S.
    Sutaria, Payal
    Qiao, Yuanyuan
    Zheng, Yang
    Zhou, Yang
    Zhang, Jinwei
    Huang, Weixue
    Ren, Xiaomei
    Wang, Zhen
    Ding, Ke
    Chinnaiyan, Arul M.
    Zhou, Fengtao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 281
  • [3] Discovery of highly potent novel antifungal azoles by structure-based rational design
    Wang, Wenya
    Sheng, Chunquan
    Che, Xiaoying
    Ji, Haitao
    Cao, Yongbing
    Miao, Zhenyuan
    Yao, Jianzhong
    Zhang, Wannian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (20) : 5965 - 5969
  • [4] Structure-based design and discovery of potent and selective KDM5 inhibitors
    Nie, Zhe
    Shi, Lihong
    Lai, Chon
    O'Connell, Shawn M.
    Xu, Jiangchun
    Stansfield, Ryan K.
    Hosfield, David J.
    Veal, James M.
    Stafford, Jeffrey A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (09) : 1490 - 1494
  • [5] Structure-Based Design of a Macrocyclic PROTAC
    Testa, Andrea
    Hughes, Scott J.
    Lucas, Xavier
    Wright, Jane E.
    Ciulli, Alessio
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2020, 59 (04) : 1727 - 1734
  • [6] Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader
    Kaneshige, Atsunori
    Yang, Yiqing
    Bai, Longchuan
    Wang, Mi
    Xu, Renqi
    Mallik, Leena
    Chinnaswamy, Krishnapriya
    Metwally, Hoda
    Wang, Yu
    McEachern, Donna
    Tosovic, Jelena
    Yang, Chao-Yie
    Kirchhoff, Paul D.
    Meagher, Jennifer L.
    Stuckey, Jeanne A.
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2024,
  • [7] Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader
    Liu, Lianchao
    Parolia, Abhijit
    Liu, Yihan
    Hou, Caiyun
    He, Tongchen
    Qiao, Yuanyuan
    Eyunni, Sanjana
    Luo, Jie
    Li, Chungen
    Wang, Yongxing
    Zhou, Fengtao
    Huang, Weixue
    Ren, Xiaomei
    Wang, Zhen
    Chinnaiyan, Arul M.
    Ding, Ke
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (09) : 6938 - 6951
  • [8] Discovery of LHF418 as a new potent SOS1 PROTAC degrader
    Li, Huifan
    Chai, Minxue
    Chen, Yihan
    Zhou, Fengtao
    Ren, Xiaomei
    Xu, Jian
    Wang, Jian
    Wang, Zhen
    Huang, Weixue
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 103
  • [9] Structure-based discovery of potent and selective melatonin receptor agonists
    Patel, Nilkanth
    Huang, Xi Ping
    Grandner, Jessica M.
    Johansson, Linda C.
    Stauch, Benjamin
    McCorvy, John D.
    Liu, Yongfeng
    Roth, Bryan
    Katritch, Vsevolod
    ELIFE, 2020, 9
  • [10] Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase
    Sun, Yaoliang
    Zhang, Ying
    Chen, Xiaoai
    Yu, Aisong
    Du, Wenhao
    Huang, Yuting
    Wu, Feifei
    Yu, Lei
    Li, Jiayi
    Wen, Cuiyun
    Yang, Hong
    Shi, Qiongyu
    Geng, Meiyu
    Huang, Xun
    Xu, Shilin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 239